Changing Services, Changing Oncology Pharmacy COVID-19 Position Statement

During the COVID-19 pandemic, oncology pharmacy services have had to adapt quickly and innovatively to continue to provide care to cancer patients. This document outlines both the clinical and operational responses implemented by BOPA members during the initial phase of COVID-19.

For clinical services we summarise different examples of responses , the key role oncology pharmacy services play in this response and recommendations for continued oncology pharmacy involvement in the future.
For operational services we identify the benefits, opportunities, risks and challenges of the responses and further considerations for reviewing these responses.

The document also highlights some of the next steps oncology pharmacy services and the wider oncology service could take in planning for the future phase of the COVID-19 pandemic.

We hope BOPA members find this document useful as it shows how we in oncology pharmacy have a pivotal role in providing cancer care and that whatever the challenges of continuing to provide care in a post COVID-19 world, so long as we plan for the risks, take opportunities, prepare to adapt and share our learning as a community, we will be able to meet them.

To access the document you must be a free or paid member of BOPA.
https://www.bopa.org.uk/resources/changing-services-changing-oncology-pharmacy-covid-19-position-statement/ 

Latest News

By UK SACT Protocols Pilot Team on 20th November 2026

Have Your Say: Review the First UK SACT Protocol and Provide Feedback

Dear Colleagues working in cancer services We are writing to invite you to review and provide feedback on the first protocol produced as part of the UK SACT Protocols Pilot.…

Read article
By Mohammed Patel on 11th November 2026

UK BMT Pharmacists Group Educational Meeting – Friday 13th November 2026. Time:14:00 to 16:00

The next UK BMT Pharmacists Group Educational Meeting is on Friday 13th November, 2pm–4pm. The sessions include: Maintenance Therapy for AML After Allogeneic BMT with Dr Mili Shah, Consultant Haematologist,…

Read article
By UK SACT Board on 9th November 2026

New UK SACT Board National Intrathecal and Intraventricular SACT Guidance

Dear colleagues, We are pleased to share the newly published UK SACT Board National Guidance on the Safe Administration of Systemic Anti-Cancer Therapies via the Intrathecal or Intraventricular Routes. This…

Read article
By BOPA Executive Committee on 9th November 2026

BOPA members flying the flag for cancer pharmacy at ESMO 2026

It was fantastic to see BOPA members representing cancer pharmacy at ESMO Congress 2026 in Madrid, which brought together the global cancer community from 23 to 27 October to share…

Read article